Cencora, Inc.
Business Model Analysis
How Cencora Makes Money
Annual Revenue: $321.3B
Cencora generates revenue primarily through Healthcare Distribution and Specialty Pharmacy, with roughly $321.3B in annual revenue.
Core Growth Engine: Cencora calls its strategy pharmaceutical-centric. Since 2024 it has redeployed capital toward specialty care: it bought about 85% of Retina Consultants of America for roughly $4.6 billion (closed January 2025) and agree...
Revenue Model & Pricing
Cencora makes money on volume and services rather than markups alone. It buys medicines from manufacturers, holds them in a national network of distribution centers and delivers them, often overnight, to pharmacies, hospitals, clinics and physician offices. Revenue is enormous because the full drug price passes through its books, but adjusted gross margin is only around 4% (4.16% in the June 2026 quarter). Profit comes from distribution service fees paid by manufacturers, generic-drug sourcing, specialty distribution of oncology and other biologics, and services such as World Courier clinical-trial logistics, commercialization and market-access consulting, and management services organizations (MSOs) for retina and oncology practices.
Core Revenue Streams
U.S. Healthcare Solutions
MajorityWholesale distribution of branded, specialty brand, generic, over-the-counter, home healthcare, and related products to pharmacies, hospitals, physicians, and alternate-care providers.
International Healthcare Solutions
Large secondary platformPharmaceutical wholesale, specialty logistics, commercialization, regulatory, and market-access services across international markets.
Specialty and Provider Services
Strategic growth areaServices for specialty providers, manufacturers, oncology and retina practices, cold-chain movement, commercialization support, and patient access.
Growth Strategy
Cencora calls its strategy pharmaceutical-centric. Since 2024 it has redeployed capital toward specialty care: it bought about 85% of Retina Consultants of America for roughly $4.6 billion (closed January 2025) and agreed in December 2025 to buy the majority of OneOncology it did not already own from TPG and others for about $3.6 billion (closed February 2026). In February 2026 it agreed to merge MWI Animal Health into Covetrus, keeping a minority stake, which narrows its focus on human pharmaceuticals. International growth comes through Alliance Healthcare in Europe, Innomar in Canada and World Courier specialty logistics.
How Cencora Makes Money: FAQ
How does Cencora generate revenue in pharmaceutical wholesale distribution?
Cencora generates revenue primarily by purchasing pharmaceuticals in bulk directly from over 1,500 drug manufacturers and distributing them daily to retail chain pharmacies (Walgreens), independent pharmacies, hospitals, mail-order pharmacies, physician practices, and veterinary clinics with small wholesale distribution fee markups.
What is Cencora's fee-for-service agreement model with pharmaceutical manufacturers?
Cencora negotiates multi-year Fee-for-Service (FFS) distribution contracts with brand drug manufacturers, receiving guaranteed administrative fees for providing inventory management, cold-chain warehousing, order tracking, and product recall management.
How does Cencora monetize generic pharmaceuticals through Walgreens Boots Alliance Development (WBAD)?
Through WBAD (a joint generic sourcing partnership with Walgreens Boots Alliance based in Switzerland), Cencora leverages large global purchasing volume to negotiate steep volume discounts on generic drugs from manufacturers, capturing higher gross profit margins.
What is Cencora's Specialty Healthcare and Oncology distribution model?
Cencora distributes high-cost oncology biologics, rheumatology treatments, and specialty injectable therapies to physician practices, specialty clinics, and health systems, providing practice management software (IntelliDose), Group Purchasing Organization (GPO) discounts via ION Solutions, and clinical research support.
How does Alliance Healthcare operate within Cencora's business model?
Alliance Healthcare (acquired from Walgreens in 2021) is one of Europe's largest pharmaceutical wholesalers, delivering medicines to more than 115,000 pharmacies, hospitals, and medical centers across the UK, France, Spain, Germany, and other European markets.
What is MWI Animal Health and how does it generate revenue?
MWI Animal Health (a Cencora company) is a leading distributor of veterinary pharmaceuticals, vaccines, surgical supplies, and practice management technology to companion animal veterinary clinics and livestock production facilities across North America and the UK.
How does Cencora monetize biopharma commercialization and patient support services?
Cencora provides biopharmaceutical manufacturers with commercialization services, including reimbursement support, prior authorization processing, copay assistance cards, clinical nurse educators, health economics and outcomes research (HEOR), and pharmacovigilance consulting.
Why is high asset and inventory turnover critical to Cencora's low-margin business model?
Pharmaceutical wholesaling earns very low margins. Cencora's adjusted gross margin was 4.16% in the June 2026 quarter and its net margin is around half a percent, so the business depends on huge volume ($321.3 billion of FY2025 revenue), fast inventory turnover and tight working-capital management.
How does Cencora make money?
Cencora operates in a massive oligopoly, generating hundreds of billions in revenue by buying massive quantities of prescription drugs and securely distributing them daily to retail pharmacies, hospitals, and specialty clinics.
Related Monetization Mechanics
Compare revenue streams, unit economics, and business models
Explore Cencora
Core profile pages, founders and related research hubs for this company.